Skip to Main Content
Contribute Try STAT+ Today

The new version of the North American Free Trade Agreement between the U.S., Canada, and Mexico is prompting concerns among generic drug makers and consumer advocates who argue language that is designed to bolster intellectual property rights for medicines will hurt taxpayers and patients.

At issue is a provision that would grant 10 years of marketing exclusivity for biologics, which are pricey medicines used to combat a wide variety of diseases, including many cancers. The language means that a company that wants to sell a lower-cost version of a brand-name biologic, which is known as a biosimilar, would be prevented from doing so for a decade.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.